目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 List of secondary sources
2.1.1.2 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 List of primary sources
2.1.2.2 Key data from primary sources
2.1.2.3 Breakdown of primary interviews
2.1.2.4 Insights from industry experts
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Approach 1: Revenue estimation of key players
2.2.1.2 Approach 2: Study of annual reports and investor presentations
2.2.1.3 Approach 3: Primary interviews
2.2.1.4 Growth forecast
2.2.1.5 CAGR projections
2.2.2 TOP-DOWN APPROACH
2.3 DATA TRIANGULATION
2.4 RESEARCH ASSUMPTIONS
2.4.1 STUDY-RELATED ASSUMPTIONS
2.4.2 PARAMETRIC ASSUMPTIONS
2.4.3 GROWTH RATE ASSUMPTIONS
2.5 RESEARCH LIMITATIONS
2.6 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN PELVIC ORGAN PROLAPSE/ PELVIC FLOOR RECONSTRUCTION MARKET
4.2 ASIA PACIFIC PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER AND COUNTRY
4.3 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY REGION
4.4 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY COUNTRY

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Global prevalence of pelvic organ prolapse
5.2.1.2 Rise in female geriatric population
5.2.1.3 Improved awareness and early diagnosis
5.2.1.4 Advancements in robotic surgical techniques
5.2.2 RESTRAINTS
5.2.2.1 Complications and recalls associated with transvaginal synthetic mesh
5.2.2.2 Limited access in emerging economies
5.2.2.3 Underdiagnosis due to social stigma
5.2.3 OPPORTUNITIES
5.2.3.1 Increased investments in pelvic organ prolapse care from emerging economies
5.2.3.2 Rapid development of bioengineered and absorbable mesh
5.2.3.3 Advent of digital pelvic health solutions
5.2.4 CHALLENGES
5.2.4.1 Inconsistent clinical guidelines and treatment standards
5.2.4.2 High recurrence and reoperation rates
5.3 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND, BY PRODUCT
5.4.2 AVERAGE SELLING PRICE TREND, BY TREATMENT AND KEY PLAYER
5.4.3 AVERAGE SELLING PRICE TREND, BY REGION
5.5 VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 INVESTMENT AND FUNDING SCENARIO
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.1.1 Pelvic mesh implants
5.9.1.2 Vaginal pessaries
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.2.1 Wearable and app-based pelvic therapy devices
5.9.3 ADJACENT TECHNOLOGIES
5.9.3.1 Urinary incontinence devices
5.10 PATENT ANALYSIS
5.11 TRADE ANALYSIS
5.11.1 IMPORT SCENARIO (HS CODE 901890)
5.11.2 EXPORT SCENARIO (HS CODE 901890)
5.12 KEY CONFERENCES AND EVENTS, 2025-2026
5.13 CASE STUDY ANALYSIS
5.13.1 NEGLECTED PESSARY IN PATIENT WITH PELVIC ORGAN PROLAPSE
5.13.2 SUCCESSFUL USE OF PESSARY FOR UTERINE PROLAPSE AFTER PELVIC TRAUMA IN YOUNG, NULLIPAROUS FEMALE
5.13.3 ROBOTIC AND LAPAROSCOPIC SACROCOLPOPEXY FOR PELVIC ORGAN PROLAPSE
5.14 REGULATORY LANDSCAPE
5.14.1 REGULATORY ANALYSIS
5.14.1.1 North America
5.14.1.1.1 US
5.14.1.1.2 Canada
5.14.1.2 Europe
5.14.1.2.1 Germany
5.14.1.2.2 UK
5.14.1.2.3 France
5.14.1.3 Asia Pacific
5.14.1.3.1 China
5.14.1.3.2 Japan
5.14.1.3.3 India
5.14.1.4 Latin America
5.14.1.5 Middle East
5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.15 PORTER'S FIVE FORCES ANALYSIS
5.15.1 BARGAINING POWER OF SUPPLIERS
5.15.2 BARGAINING POWER OF BUYERS
5.15.3 THREAT FROM NEW ENTRANTS
5.15.4 THREAT FROM SUBSTITUTES
5.15.5 INTENSITY OF COMPETITIVE RIVALRY
5.16 KEY STAKEHOLDERS AND BUYING CRITERIA
5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.16.2 BUYING CRITERIA
5.17 IMPACT OF AI
5.17.1 INTRODUCTION
5.17.2 POTENTIAL OF AI IN PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET
5.17.3 KEY COMPANIES IMPLEMENTING AI
5.17.4 FUTURE OF AI IN PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET
5.18 US 2025 TARIFF
5.18.1 INTRODUCTION
5.18.2 KEY TARIFF RATES
5.18.3 PRICE IMPACT ANALYSIS
5.18.4 IMPACT ON COUNTRY/REGION
5.18.4.1 North America
5.18.4.2 Europe
5.18.4.3 Asia Pacific
5.18.5 IMPACT ON END-USE INDUSTRIES
5.18.5.1 Hospitals

6 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 SYNTHETIC MESH
6.2.1 ADOPTION OF ADVANCED, PATIENT-FOCUSED MESH TECHNOLOGIES
6.3 BIOLOGICAL GRAFTS
6.3.1 SHIFT TOWARD BIOCOMPATIBLE ALTERNATIVES
6.4 SUTURES
6.4.1 NEED FOR PRECISION IN PELVIC REPAIRS WITH ABSORBABLE AND ANTIBACTERIAL PRODUCTS
6.5 VAGINAL PESSARIES
6.5.1 INTRODUCTION OF CUSTOM-FIT, HOME-USE PESSARY SOLUTIONS
6.6 PELVIC FLOOR THERAPY DEVICES
6.6.1 PATIENT PREFERENCE FOR MANAGING PELVIC FLOOR DISORDERS INDEPENDENTLY
6.7 ROBOTIC SURGERY SYSTEMS
6.7.1 ELEVATED DEMAND FOR MINIMALLY INVASIVE SOLUTIONS IN COMPLEX PELVIC REPAIRS
6.8 DIAGNOSTIC & ASSESSMENT TOOLS
6.8.1 ACCURATE DETECTION WITH ADVANCED IMAGING AND SMART DEVICES

7 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TREATMENT
7.1 INTRODUCTION
7.2 SURGICAL
7.2.1 COLPOCLEISIS
7.2.1.1 Large-scale adoption among older women
7.2.2 COLPORRHAPY
7.2.2.1 Increased preference for foundational repair techniques
7.2.3 SACROCOLPOPEXY
7.2.3.1 Reduced postoperative discomfort and quicker recovery
7.2.4 SACROHYSTEROPEXY
7.2.4.1 Rise in demand for uterine-preserving options for prolapse repair
7.2.5 UTEROSACRAL OR SACROSPINOUS LIGAMENT FIXATION
7.2.5.1 Surge in native tissue repairs without mesh-based interventions
7.3 NON-SURGICAL
7.3.1 VAGINAL PESSARY MANAGEMENT
7.3.1.1 Emphasis on early intervention
7.3.2 PELVIC FLOOR MUSCLE THERAPY
7.3.2.1 Extensive use in early-stage prolapse and postpartum women

8 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY APPLICATION
8.1 INTRODUCTION
8.2 CYSTOCELE
8.2.1 WEAKENED PELVIC FLOOR MUSCLES PROMPT DEVELOPMENT
8.3 URETHROCELE
8.3.1 CHRONIC INCREASE IN INTRA-ABDOMINAL PRESSURE
8.4 ENTEROCELE
8.4.1 SURGE IN APICAL VAGINAL SUPPORT DEFICIENCY
8.5 UTERINE PROLAPSE
8.5.1 GROWTH IN PROLAPSE BURDEN
8.6 RECTOCELE
8.6.1 PREVALENCE OF RECTOVAGINAL SEPTUM DEFICIENCY

9 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER
9.1 INTRODUCTION
9.2 HOSPITALS
9.2.1 HIGH PATIENT INFLOW AND WIDESPREAD AVAILABILITY OF REIMBURSEMENTS
9.3 SPECIALTY CLINICS
9.3.1 HEIGHTENED DEMAND FOR TAILORED, NON-INVASIVE, AND ACCESSIBLE CARE
9.4 AMBULATORY SURGERY CENTERS
9.4.1 COST ADVANTAGES AND FAVORABLE CLINICAL OUTCOMES
9.5 OTHER END USERS

10 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 MACROECONOMIC OUTLOOK
10.2.2 US
10.2.2.1 Rise in female geriatric population to drive market
10.2.3 CANADA
10.2.3.1 High symptom prevalence and demographic trends to drive market
10.3 EUROPE
10.3.1 MACROECONOMIC OUTLOOK
10.3.2 GERMANY
10.3.2.1 Advanced surgical innovations to drive market
10.3.3 FRANCE
10.3.3.1 Increased clinical focus on pelvic floor disorders and pelvic organ prolapse to drive market
10.3.4 UK
10.3.4.1 Women's health policy initiatives to drive market
10.3.5 ITALY
10.3.5.1 Demographic shifts to drive market
10.3.6 SPAIN
10.3.6.1 Rising popularity of non-surgical interventions to drive market
10.3.7 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 MACROECONOMIC OUTLOOK
10.4.2 CHINA
10.4.2.1 Growing incidence of pelvic organ prolapse to drive market
10.4.3 JAPAN
10.4.3.1 Evolving healthcare delivery and infrastructure landscape to drive market
10.4.4 INDIA
10.4.4.1 Booming medical tourism to drive market
10.4.5 AUSTRALIA
10.4.5.1 Rapid growth of medical manufacturing companies to drive market
10.4.6 SOUTH KOREA
10.4.6.1 Surge in healthcare spending to drive market
10.4.7 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
10.5.1 MACROECONOMIC OUTLOOK
10.5.2 BRAZIL
10.5.2.1 Improving healthcare infrastructure to drive market
10.5.3 MEXICO
10.5.3.1 Expanding healthcare awareness and services to drive market
10.5.4 REST OF LATIN AMERICA
10.6 MIDDLE EAST & AFRICA
10.6.1 MACROECONOMIC OUTLOOK

11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2022-2025
11.3 REVENUE ANALYSIS, 2022-2024
11.4 MARKET SHARE ANALYSIS, 2024
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
11.5.5 COMPANY FOOTPRINT
11.5.5.1 Company footprint
11.5.5.2 Region footprint
11.5.5.3 Product footprint
11.5.5.4 Treatment footprint
11.5.5.5 Application footprint
11.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2024
11.6.1 PROGRESSIVE COMPANIES
11.6.2 RESPONSIVE COMPANIES
11.6.3 DYNAMIC COMPANIES
11.6.4 STARTING BLOCKS
11.6.5 COMPETITIVE BENCHMARKING
11.6.5.1 List of start-ups/SMEs
11.6.5.2 Competitive benchmarking of start-ups/SMEs
11.7 COMPANY VALUATION AND FINANCIAL METRICS
11.8 BRAND/PRODUCT COMPARISON
11.9 COMPETITIVE SCENARIO
11.9.1 PRODUCT LAUNCHES/APPROVALS
11.9.2 DEALS
11.9.3 OTHER DEVELOPMENTS

12 COMPANY PROFILES
12.1 KEY PLAYERS
12.1.1 BOSTON SCIENTIFIC CORPORATION
12.1.1.1 Business overview
12.1.1.2 Products offered
12.1.1.3 Recent developments
12.1.1.3.1 Deals
12.1.1.4 MnM view
12.1.1.4.1 Right to win
12.1.1.4.2 Strategic choices
12.1.1.4.3 Weaknesses and competitive threats
12.1.2 COLOPLAST GROUP
12.1.2.1 Business overview
12.1.2.2 Products offered
12.1.2.3 MnM view
12.1.2.3.1 Right to win
12.1.2.3.2 Strategic choices
12.1.2.3.3 Weaknesses and competitive threats
12.1.3 INTUITIVE SURGICAL OPERATIONS, INC.
12.1.3.1 Business overview
12.1.3.2 Products offered
12.1.3.3 Recent developments
12.1.3.3.1 Product launches/approvals
12.1.3.4 MnM view
12.1.3.4.1 Right to win
12.1.3.4.2 Strategic choices
12.1.3.4.3 Weaknesses and competitive threats
12.1.4 COOPERCOMPANIES
12.1.4.1 Business overview
12.1.4.2 Products offered
12.1.4.3 Recent developments
12.1.4.3.1 Deals
12.1.4.4 MnM view
12.1.4.4.1 Right to win
12.1.4.4.2 Strategic choices
12.1.4.4.3 Weaknesses and competitive threats
12.1.5 JOHNSON & JOHNSON
12.1.5.1 Business overview
12.1.5.2 Products offered
12.1.5.3 Recent developments
12.1.5.3.1 Product launches/approvals
12.1.5.3.2 Deals
12.1.5.3.3 Other developments
12.1.5.4 MnM view
12.1.5.4.1 Right to win
12.1.5.4.2 Strategic choices
12.1.5.4.3 Weaknesses and competitive threats
12.1.6 GE HEALTHCARE
12.1.6.1 Business overview
12.1.6.2 Products offered
12.1.6.3 Recent developments
12.1.6.3.1 Product launches/approvals
12.1.6.3.2 Deals
12.1.6.3.3 Other developments
12.1.7 INTEGRA LIFESCIENCES CORPORATION
12.1.7.1 Business overview
12.1.7.2 Products offered
12.1.8 B. BRAUN SE
12.1.8.1 Business overview
12.1.8.2 Products offered
12.1.8.3 Recent developments
12.1.8.3.1 Deals
12.1.9 PFM MEDICAL GMBH
12.1.9.1 Business overview
12.1.9.2 Products offered
12.1.10 CALDERA MEDICAL
12.1.10.1 Business overview
12.1.10.2 Products offered
12.1.10.3 Recent developments
12.1.10.3.1 Deals
12.2 OTHER PLAYERS
12.2.1 KEGEL8
12.2.2 MEDGYN PRODUCTS INC.
12.2.3 BETATECH MEDICAL
12.2.4 FEG TEXTILTECHNIK FORSCHUNGS- UND ENTWICKLUNGSGESELLSCHAFT MBH
12.2.5 BIOTEQUE AMERICA INC.
12.2.6 PERSONAL MEDICAL CORP.
12.2.7 DIPROMED SRL
12.2.8 A.M.I. GMBH
12.2.9 BRAY GROUP
12.2.10 DIGITIMER LTD
12.2.11 MEDESIGN I.C. GMBH
12.2.12 DR. ARABIN GMBH & CO. KG
12.2.13 FOR.ME.SA.
12.2.14 COSM MEDICAL
12.2.15 WILLOW INNOVATIONS, INC.

13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS